30 closest matches · ranked by relevance
Satisfaction · Trauma
Primary: Patient Satisfaction as Measured by Giving an "Excellent" Score on a 5-point Rating — 25; 22 participants
Pulmonary Disease, Chronic Obstructive
Primary: The Patients' Satisfaction With Chronic Obstructive Pulmonary Disease (COPD) Medical Treatments During a 12-month Observation Period — 64.2; 66.2; 67.1; 75.8 Unit on Scale
Outcome Assessment · Patient Satisfaction
Primary: Overall Patient Satisfaction — 247; 53 Participants
Patient Satisfaction
Primary: Patient Satisfaction With Pain Control in Labor — 5; 5 score on a scale — p=0.16
Satisfaction
Primary: Anxiety — 2.9; 1.4 NRS
Critical Illness
Primary: Family Satisfaction in the ICU (FS-ICU) Questionnaire- Overall Satisfaction Score — 78.3 units on a scale
Psoriasis
Primary: Participant Satisfaction With Injection Device Evaluated at Week 12 for Modified Intent-to-treat (mITT) Population — 8.9; 7.6 units on a scale — p=<0.001
Relapsing-Remitting Multiple Sclerosis (RRMS)
Primary: Change From Baseline in Convenience Satisfaction Score of Treatment Satisfaction Questionnaire to Medication (TSQM-9) at Week 12 — 38.5; 38.5 score on a scale — p=0.56
Postoperative Pain
Primary: Patient Satisfaction Questionnaire — 8; 7.5 units on a scale
Myopia
Primary: Subject Satisfaction — 50 Participants
Colon Cancer · IBS · Polyps
Primary: Patient Satisfaction — 259; 222; 37; 66 Participants
Rheumatoid Arthritis
Primary: Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 — 62.271; 64.191; 93.390; 96.603 units on a scale — p=0.3648
Glabellar Frown Lines
Primary: Subject Satisfaction When Treated With abobutulinumtoxinA in Their Glabellar Lines — 66; 38; 4; 2 Participants
Patient Satisfaction
Primary: Patient Satisfaction — 120; 116 units on a scale
Obstructive Sleep Apnea
Primary: To Determine the Association of the Participants Baseline PPQ (Patient Perception Questionnaire) Responses to Predict Adherence to CPAP Treatment at 90 Days. — .04; .14…
Diabetes type1
Primary: Number of Participants With Satisfaction Regarding the Management in General, at Day 30 and Day 90, by the CSQ-8 Questionnaire — 35; 35 Participants
Patient Compliance
Primary: Number of Cases Postponed Due to Lack of Information to Patients in the Pre-operative Period — 56; 44 Participants
Anxiety
Primary: State-Trait Anxiety Inventory-State Scores — 37.9; 40.7; NA; 37.7 units on a scale
Allergic Rhinitis
Primary: Overall Best-Worst Scaling Task Index Score (Treatment Satisfaction Index Score) — 68.26; 62.78 units on a scale — p=<.001
Glabellar Frown Lines
Primary: Percentage of Participants With Improvement in Subject Global Assessment of Change at Day 30 — 94.7; 0.00 Percentage of participants
Hepatitis C, Chronic · Hepacivirus
Primary: Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use. — 104; 102; 102; 102 Satisfied Participants
Schizophrenia
Primary: Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to the Week 6 Endpoint. — 2.5; 2.3; 2.4 Points on a scale — p=<0.001
Ultrasound
Primary: Patient Satisfaction — 87.6; 83.9 units on a scale
Pelvic Floor Disorders
Primary: Patient Satisfaction — 100; 94 score on a scale — p==0.002
Atrial Fibrillation
Primary: Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment…
Hepatitis C, Chronic · Hepatitis C
Primary: Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey. — 6.16 Units on a scale
Arthroplasty, Replacement, Knee · Arthroplasty, Replacement, Hip
Primary: Percentage of Participants Reporting a Problem Across al PPE-15 Domains — 12.6; 9.5 percent of participants
Plaque Psoriasis
Primary: Change in Investigator's Global Assessment Grade — -0.8 units on a scale
Skin Aging
Primary: The First Visit Onset of Efficacy as Measured by Physician Assessment — 2.2 Number of Days
Head and Neck Cancer · Acute Pain · Postoperative Pain
Primary: Change in Daily Narcotic Consumption — 1.60; 1.59 mg/hour